Antagonising the expression of VEGF in pathological angiogenesis

被引：4

作者：

Brenchley, PEC ^{[1
]}

机构：

[1] Manchester Royal Infirm, Inst Nephrol & Transplantat, Manchester M13 9WL, Lancs, England

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 1998年 / 8卷 / 12期

关键词：

angiogenesis; vascular endothelial growth factor (VEGF); vascular permeability; VEGF antagonists; VEGF receptors;

D O I：

10.1517/13543776.8.12.1695

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Vascular endothelial growth factor (VEGF) is the prototype of a subfamily of five growth factors sharing structural homologies with the platelet-derived growth factor (PDGF) protein superfamily. The VEGFs are potent mitogens specific for endothelial cells of the blood or lymphatic vasculature and are effective modulators of vessel permeability in the normal physiological processes of angiogenesis and vasculogenesis. VEGF appears to be a significant promoter of the inappropriate angiogenesis that sustains tumour growth and metastasis, inflammatory joint disease and diabetic retinopathy. Understanding the cell biology and control of VEGF expression has led to the development of several strategies for antagonising the pathological angiogenesis associated with these common diseases. This review describes these promising approaches in the context of current understanding of VEGF biology.

引用

页码：1695 / 1706

页数：12

共 125 条

[1]

Agani F, 1997, CANCER RES, V57, P4474

[2] SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS [J].

AIELLO, LP ;

PIERCE, EA ;

FOLEY, ED ;

TAKAGI, H ;

CHEN, H ;

RIDDLE, L ;

FERRARA, N ;

KING, GL ;

SMITH, LEH .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10457-10461

[3] VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].

AIELLO, LP ;

AVERY, RL ;

ARRIGG, PG ;

KEYT, BA ;

JAMPEL, HD ;

SHAH, ST ;

PASQUALE, LR ;

THIEME, H ;

IWAMOTO, MA ;

PARK, JE ;

NGUYEN, HV ;

AIELLO, LM ;

FERRARA, N ;

KING, GL .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487

[4] Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription [J].

Akiri, G ;

Nahari, D ;

Finkelstein, Y ;

Le, SY ;

Elroy-Stein, O ;

Levi, BZ .

ONCOGENE, 1998, 17 (02) :227-236

[5] Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer [J].

Anan, K ;

Morisaki, T ;

Katano, M ;

Ikubo, A ;

Kitsuki, H ;

Uchiyama, A ;

Kuroki, S ;

Tanaka, M ;

Torisu, M .

SURGERY, 1996, 119 (03) :333-339

[6] An essential role for p300/CBP in the cellular response to hypoxia [J].

Arany, Z ;

Huang, LE ;

Eckner, R ;

Bhattacharya, S ;

Jiang, C ;

Goldberg, MA ;

Bunn, HF ;

Livingston, DM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (23) :12969-12973

[7] UP-REGULATION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR EXPRESSION INDUCED BY MYOCARDIAL-ISCHEMIA - IMPLICATIONS FOR CORONARY ANGIOGENESIS [J].

BANAI, S ;

SHWEIKI, D ;

PINSON, A ;

CHANDRA, M ;

LAZAROVICI, G ;

KESHET, E .

CARDIOVASCULAR RESEARCH, 1994, 28 (08) :1176-1179

[8] Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1 [J].

Barleon, B ;

Sozzani, S ;

Zhou, D ;

Weich, HA ;

Mantovani, A ;

Marme, D .

BLOOD, 1996, 87 (08) :3336-3343

[9] VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) GENE IS EXPRESSED DIFFERENTIALLY IN NORMAL-TISSUES, MACROPHAGES, AND TUMORS [J].

BERSE, B ;

BROWN, LF ;

VANDEWATER, L ;

DVORAK, HF ;

SENGER, DR .

MOLECULAR BIOLOGY OF THE CELL, 1992, 3 (02) :211-220

[10]

Bottomley Martyn J., 1996, Arthritis and Rheumatism, V39, pS131

← 1 2 3 4 5 6 7 8 9 10 →